UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in Amylyx Pharmaceuticals, Inc. $AMLX

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) by 10.4% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 173,407 shares of the company’s stock after acquiring an additional 16,318 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Amylyx Pharmaceuticals were worth $3,114,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. BlackRock Inc. acquired a new position in shares of Amylyx Pharmaceuticals in the 2nd quarter worth approximately $158,534,000. Jupiter Topco LLC acquired a new stake in Amylyx Pharmaceuticals in the 2nd quarter valued at approximately $94,014,000. Adage Capital Partners GP L.L.C. increased its holdings in Amylyx Pharmaceuticals by 54.5% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock valued at $56,408,000 after purchasing an additional 3,102,395 shares during the last quarter. Millennium Management LLC raised its position in Amylyx Pharmaceuticals by 418.6% in the first quarter. Millennium Management LLC now owns 3,081,853 shares of the company’s stock valued at $10,910,000 after purchasing an additional 2,487,617 shares during the period. Finally, Janus Henderson Group PLC raised its position in Amylyx Pharmaceuticals by 76.1% in the fourth quarter. Janus Henderson Group PLC now owns 4,465,872 shares of the company’s stock valued at $53,992,000 after purchasing an additional 1,929,639 shares during the period. 95.84% of the stock is owned by hedge funds and other institutional investors.

Amylyx Pharmaceuticals Stock Performance

Shares of AMLX stock opened at $32.09 on Friday. Amylyx Pharmaceuticals, Inc. has a fifty-two week low of $10.83 and a fifty-two week high of $41.14. The company has a 50 day moving average price of $25.43 and a 200 day moving average price of $18.74. The stock has a market capitalization of $3.58 billion, a P/E ratio of -22.44 and a beta of -0.13.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.03). On average, research analysts forecast that Amylyx Pharmaceuticals, Inc. will post -1.48 EPS for the current fiscal year.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other news, insider Gina Mazzariello sold 15,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $18.32, for a total transaction of $274,800.00. Following the sale, the insider owned 194,090 shares of the company’s stock, valued at approximately $3,555,728.80. This represents a 7.17% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 10.90% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. Wolfe Research upgraded Amylyx Pharmaceuticals to a “strong-buy” rating in a research note on Monday, August 17th. Mizuho lifted their price objective on Amylyx Pharmaceuticals from $30.00 to $42.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Guggenheim boosted their price objective on Amylyx Pharmaceuticals from $55.00 to $57.00 and gave the company a “buy” rating in a report on Thursday, August 27th. HC Wainwright increased their target price on Amylyx Pharmaceuticals from $34.00 to $55.00 and gave the stock a “buy” rating in a research note on Tuesday, August 18th. Finally, Robert W. Baird raised their target price on Amylyx Pharmaceuticals from $28.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, August 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amylyx Pharmaceuticals has a consensus rating of “Buy” and an average price target of $36.50.

About Amylyx Pharmaceuticals